30.76
0.05 (0.16%)
| Penutupan Terdahulu | 30.71 |
| Buka | 30.68 |
| Jumlah Dagangan | 476,113 |
| Purata Dagangan (3B) | 618,972 |
| Modal Pasaran | 1,716,854,016 |
| Harga / Pendapatan (P/E TTM) | 23.30 |
| Harga / Pendapatan (P/E Ke hadapan) | 20.16 |
| Harga / Jualan (P/S) | 2.61 |
| Harga / Buku (P/B) | 1.69 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 May 2025 - 12 May 2025 |
| Margin Keuntungan | 9.27% |
| Margin Operasi (TTM) | -4.67% |
| EPS Cair (TTM) | 1.11 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 4.30% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 1,204.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 3.13% |
| Nisbah Semasa (MRQ) | 2.44 |
| Aliran Tunai Operasi (OCF TTM) | 164.15 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 138.80 M |
| Pulangan Atas Aset (ROA TTM) | 2.76% |
| Pulangan Atas Ekuiti (ROE TTM) | 6.32% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Menurun | Bercampur |
| Drug Manufacturers - Specialty & Generic (Global) | Menurun | Bercampur | |
| Stok | Supernus Pharmaceuticals, Inc. | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | -2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -0.5 |
| Purata | -0.75 |
|
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 4.87% |
| % Dimiliki oleh Institusi | 109.18% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 16 Jun 2025 | Pengumuman | Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio |
| 29 May 2025 | Pengumuman | Jay Glazer and Wife Rosie Glazer Offer Candid Look at ADHD and Relationships in New Qelbree® Content Series with Supernus Pharmaceuticals |
| 28 May 2025 | Pengumuman | Supernus Announces Paragraph IV ANDA Filings for Qelbree® |
| 28 May 2025 | Pengumuman | Supernus to Participate in the 2025 Jefferies Global Healthcare Conference |
| 20 May 2025 | Pengumuman | Busy Philipps Empowers Women with ADHD to Go from Feeling Misrepresented to Being ‘Ms. Represented’ in First-of-its-Kind Campaign with Supernus Pharmaceuticals |
| 06 May 2025 | Pengumuman | Supernus Announces First Quarter 2025 Financial Results |
| 23 Apr 2025 | Pengumuman | Supernus Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 6, 2025 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |